Adaptive Biotechnologies is a pioneer & leader in immune-driven medicine. We aim to improve lives by learning from the wisdom of our adaptive immune systems.
Seattle, WA. U.S.A.
- Tweets 2,617
- Following 1,301
- Followers 4,537
- Likes 638
A new consensus definition of cure in multiple myeloma marks an important milestone for patients and the myeloma community. Learn more about the new consensus definition and the role of MRD testing: adaptivebio.tech/jfy
132
MRD data continue to define new standards of care in #multiplemyeloma. An expanded analysis from the Ph 3 CEPHEUS study is a powerful example of #MRD helping differentiate therapies and move clinical practice forward.
Read the study in Blood Advances: adaptivebio.tech/pvf
159
Updated NCCN® Guidelines now include a dedicated MRD testing page, identify 10⁻⁶ as the preferred sensitivity and specifically name clonoSEQ® as an FDA-cleared assay for MRD assessment. Read more: adaptivebio.tech/98m
1
1
164
September is #BloodCancerAwarenessMonth. According to @BloodCancerUtd, every 3 minutes someone in the U.S. is diagnosed with leukemia, lymphoma or myeloma. At Adaptive, we’re committed to deeper insight and more informed decisions across the blood cancer journey.
162
Adaptive has been named a U.S. News & World Report 2026–2027 Best Company to Work For across four categories. We couldn’t be prouder. adaptivebio.tech/sfj
#BeAdaptive #BestCompanies
159
This weekend, Adaptive teammates will come together for Obliteride, each with a personal reason for showing up. Swipe to learn why Chris, Christine and Amanda #Obliteride. #BeAdaptive
2
220
clonoSEQ® MRD testing adoption is rooted in strong clinical evidence—but it also needs to work seamlessly in real-world care.
2
214
The road to @Obliteride is about more than race day—it's about coming together for a shared purpose. Adaptive teammates have hosted group trainings and rides rallying fundraising support for lifesaving cancer research. #Obliteride #BeAdaptive #CureCancerFaster #TeamAdaptive
1
162
As MRD adoption accelerates, clinical practice is evolving—especially in the community.
🎥 Jay Patel, Dir., Medical Affairs, on how clonoSEQ® is being leveraged in the community setting
3
214
As a leader within PRIDE @ Adaptive, Kirsten Wollam helps advance initiatives that strengthen inclusion, representation, and support for LGBTQ+ employees across our company.
#PrideMonth #BeAdaptive #InclusionAndBelonging
1
126
As MRD moves into routine care, what matters most is having an approach that is deeply validated, highly sensitive and specific, and widely adopted across both clinical trials and real-world practice.
🎥 Hear more from Mary Pat Lancelotta, SVP MRD Biopharma
112
Data at #ASCO2026 and #EHA2026 reinforce clonoSEQ’s role as a gold standard for assessing depth of response, longitudinal disease monitoring, and MRD-guided treatment decision-making. Explore more than 30 abstracts featuring clonoSEQ across both meetings: adaptivebio.tech/vdw
3
205
Launch your next molecular #immuneprofiling study in days — not weeks.
Adaptive has partnered with @scientist_com — giving you a faster path from idea to actionable #TCR and #BCR deep sequencing results.
Start your project today. adaptivebio.tech/kmp
1
101
What happens when models learn directly from large-scale T cell activation data?
In one benchmark, a sequence-based approach outperformed structure-based pipelines—while running much faster. adaptivebio.tech/6xq
#worldimmunologyday
1
129
How do T-cell receptors recognize antigens—and which interactions lead to activation? New work (presented at #ML4H2025) explores a data-driven approach using large-scale T-cell activation data. Read more: adaptivebio.tech/6xq
3
228
Adaptive is attending #AACR26.
We partner with biopharma teams using T- and B-cell receptor sequencing and MRD testing to advance hematology and oncology research and clinical trials.
Let’s talk about your study.
📩 bd@adaptivebiotech.com
1
184
ICYMI: Adaptive's latest webinar highlights how our TCR and BCR sequencing technologies and large-scale immune repertoire database can accelerate the development of immune-modulating therapies.
🎧 Access the recording now: adaptivebio.tech/2hj
1
292
This #MyelomaAwarenessMonth, hear from Allison Jacob, VP Medical Affairs, how MRD testing is informing care decisions across the myeloma journey. Adaptive is working to help bring better outcomes to people living with lymphoid malignancies.
1
149
There’s still time to register for our March 18 webinar ⏰
Learn how immunosequencing and large scale immune data drive smarter R&D decisions—from MoA validation to PK/PD and TCR signal detection.
👉 Register: adaptivebio.tech/dc215c
1
134
This #IWD2026, Sr. Dir. R&D Katie Husske reminds us, “each of us has something valuable to contribute—whether it’s our expertise, our time, or simply a willingness to listen.” #GiveToGain #BeAdaptive
84